Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Virginia Picanço-Castro"'
Autor:
Renata Nacasaki Silvestre, Jiri Eitler, Julia Teixeira Cottas de Azevedo, Mariane Cariati Tirapelle, Daianne Maciely Carvalho Fantacini, Lucas Eduardo Botelho de Souza, Kamilla Swiech, Dimas Tadeu Covas, Rodrigo T. Calado, Paola Ortiz Montero, Kelen Cristina Ribeiro Malmegrim, Marxa L. Figueiredo, Torsten Tonn, Virginia Picanço-Castro
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionNatural killer 92 (NK-92) cells are an attractive therapeutic approach as alternative chimeric antigen receptor (CAR) carriers, different from T cells, once they can be used in the allogeneic setting. The modest in vivo outcomes observed
Externí odkaz:
https://doaj.org/article/3c70f6d73d3641458e2db201ea935271
Autor:
Rodrigo Nalio Ramos, Virginia Picanço-Castro, Theo Gremen M. Oliveira, Alfredo Mendrone, Junior, Gil Cunha De Santis, Martin Hernan Bonamino, Vanderson Rocha
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S46-S53 (2021)
Chimeric Antigen Receptor T (CAR-T) cells are certainly an important therapy for patients with relapsed and/or refractory hematologic malignancies. Currently, there are five CAR-T cell products approved by the FDA but several research groups and/or b
Externí odkaz:
https://doaj.org/article/558a6b96477e4bcba2af415589f2cdde
Autor:
Virginia Picanço-Castro, Martín Hernan Bonamino, Rodrigo Nalio Ramos, Renato L. Guerino-Cunha, Theo Gremen M. Oliveira, Eduardo M. Rego
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S54-S63 (2021)
Currently, there are four CAR-T products commercially available on the market. CAR-T cells have shown high remission rates and they represent an effective treatment option for patients with resistant or refractory B cell malignancies. Approval of the
Externí odkaz:
https://doaj.org/article/ad7835ecd3b342c4b49161e3aaa1bacf
Autor:
Ana Luiza Oliveira Lomba, Mariane Cariati Tirapelle, Rafael Tagé Biaggio, Mário Soares Abreu-Neto, Dimas Tadeu Covas, Virginia Picanço-Castro, Kamilla Swiech, Amanda Mizukami
Publikováno v:
Brazilian Archives of Biology and Technology, Vol 64 (2021)
Abstract Human Embryonic Kidney 293T cells (HEK-293T) are the most common host for viral vector production and are also widely employed for recombinant protein production. These cells are typically cultured in monolayer (adherent culture) using cultu
Externí odkaz:
https://doaj.org/article/741ea124e9e744b2afc656ad36574e89
Autor:
Taylla Klei Felix Souza, Mariana Penteado Nucci, Javier Bustamante Mamani, Helio Rodrigues da Silva, Daianne Maciely Carvalho Fantacini, Lucas Eduardo Botelho de Souza, Virginia Picanço-Castro, Dimas Tadeu Covas, Edson Luis Vidoto, Alberto Tannús, Lionel Fernel Gamarra
Publikováno v:
PLoS ONE, Vol 13, Iss 7, p e0201453 (2018)
The primary objective of this study is to monitor tumor growth by using image techniques and behavioral testing through general and specific motor activities (spontaneous movements and gait). Our sample includes male Wistar rats, 2 months old and wei
Externí odkaz:
https://doaj.org/article/5ec1cb5309214c00afdcb9ac48467e23
Autor:
Marcela Cristina Correa de Freitas, Aparecida Maria Fontes, Andrielle de Castilho Fernandes, Virginia Picanço-Castro, Elisa Maria de Sousa Russo, Dimas Tadeu Covas
Publikováno v:
Revista Brasileira de Hematologia e Hemoterapia, Vol 36, Iss 3, Pp 213-218 (2014)
OBJECTIVE: Nowadays recombinant factor VIII is produced in murine cells including in Chinese hamster ovary (CHO) and baby hamster kidney cells (BHK). Previous studies, using the murine leukemia virus-derived retroviral vector pMFG-FVIII-P140K, modifi
Externí odkaz:
https://doaj.org/article/12f629efab7242718d19a4b276d88764
Autor:
Dayane Schmidt, Sima Ebrahimabadi, Kauan Ribeiro de Sena Gomes, Graziela de Moura Aguiar, Mariane Cariati Tirapelle, Renata Nacasaki Silvestre, Júlia Teixeira Cottas de Azevedo, Dimas Tadeu Covas, Virginia Picanço-Castro
Publikováno v:
Immunotherapy Advances. 2
Cell therapy is an innovative approach that permits numerous possibilities in the field of cancer treatment. CAR-T cells have been successfully used in patients with hematologic relapsed/refractory. However, the need for autologous sources for T cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bad7ded86a5505da4dbb025995f9e6b
https://doi.org/10.1093/immadv/ltac003
https://doi.org/10.1093/immadv/ltac003
Autor:
Bárbara C.M.F. Paes, Luiza C.J.R. Stabeli, Péricles N.M. Costa, Maristela Delgado Orellana, Simone Kashima, Dimas Tadeu Covas, Virgínia Picanço-Castro
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss 2, Pp 156-164 (2021)
Introduction: Sickle cell disease (SCD) is a monogenic disease and it is estimated that 300,000 infants are born annually with it. Most treatments available are only palliative, whereas the allogeneic hematopoietic stem cell transplantation offers th
Externí odkaz:
https://doaj.org/article/6cc75d9a477c437197bd6e40b51e1ab7
Autor:
Virgínia Picanco-Castro, Cristiano Gonçalves Pereira, Kamilla Swiech, Kelen Cristina Ribeiro Malmegrim, Dimas Tadeu Covas, Geciane Silveira Porto
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 16, Iss 6, Pp 1424-1433 (2020)
The purpose of this study is to mine CAR-T patents and therapies under development, to design a landscape of the sector and to understand key therapy segments and their current trends. The study analyzed the entire market, consisting of 1624 patent f
Externí odkaz:
https://doaj.org/article/ad24c6be49d24c66899e69c699961480
Autor:
Virgínia Picanço-Castro, Pablo Diego Moço, Amanda Mizukami, Leticia Delfini Vaz, Marcelo de Souza Fernandes Pereira, Renata Nacasaki Silvestre, Júlia Teixeira Cottas de Azevedo, Aline de Sousa Bomfim, Mario Soares de Abreu Neto, Kelen Cristina Ribeiro Malmegrim, Kamilla Swiech, Dimas Tadeu Covas
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 42, Iss 2, Pp 150-158 (2020)
Introduction: Adoptive transfer of T cells expressing a CD19-specific chimeric antigen receptor (CAR) has shown impressive response rates for the treatment of CD19 + B-cell malignancies in numerous clinical trials. The CAR molecule, which recognizes
Externí odkaz:
https://doaj.org/article/46b2df83e5f24db88e2dd8999c65cfb5